Hepatocellular carcinoma is a common, difficult-to-treat cancer that has a
variable natural history depending on patient demographics and the etiology
and extent of underlying liver disease. Resection is the preferred treatme
nt option but is only possible in the rare patient who has adequate hepatic
reserve and limited-stage cancer. Systemic chemotherapy is mostly inactive
. Because most patients with hepatocellular cancer succumb to hepatic failu
re, this is a disease that appears to be amenable to regional treatments. F
or this reason, numerous intratumoral, ablative techniques are available, O
ther routinely used regional treatment modalities include intraarterial che
motherapy, chemoembolization, Lipiodol chemoembolization, and internal radi
ation. However, the benefits of these interventions have been difficult to
ascertain given the variable clinical course of the disease. Regional deliv
ery may prove to be most valuable as a route for administering newer agents
.